Margaret L Axelrod

7PUBLICATIONS
73CO-AUTHORS
Predictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Toxicology (incl. clinical toxicology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Apr 22, 2026
Peripheral blood transcriptional profiling predicts tumor subtype and neoadjuvant chemoimmunotherapy outcomes in human breast cancer.

|Nov 17, 2022
T cells specific for α-myosin drive immunotherapy-related myocarditis.

Margaret L Axelrod, Wouter C Meijers, Elles M Screever

|Jul 28, 2021
Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti-PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast Cancer.

Paula I Gonzalez-Ericsson, Julia D Wulfkhule, Rosa I Gallagher

|May 07, 2021
Progesterone promotes immunomodulation and tumor development in the murine mammary gland.

Lauryn R Werner, Katelin A Gibson, Merit L Goodman

|Dec 01, 2020
A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitor-Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention.

Spencer C Wei, Wouter C Meijers, Margaret L Axelrod

|Aug 23, 2020
Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer.

Margaret L Axelrod, Mellissa J Nixon, Paula I Gonzalez-Ericsson

Pageof 2

Frequent Collaborators

6 joint publications

Justin M Balko

2 joint publications

Elizabeth C Wescott

2 joint publications

Melinda Sanders

2 joint publications

Paula I Gonzalez-Ericsson